109 related articles for article (PubMed ID: 35605404)
1. Reduction of phosphorylated α-synuclein through downregulation of casein kinase 2α alleviates dopaminergic-neuronal function.
Potdar C; Kaushal A; Raj A; Mallick R; Datta I
Biochem Biophys Res Commun; 2022 Jul; 615():43-48. PubMed ID: 35605404
[TBL] [Abstract][Full Text] [Related]
2. Influence of 6-Hydroxydopamine Toxicity on α-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release.
Ganapathy K; Datta I; Sowmithra S; Joshi P; Bhonde R
J Cell Biochem; 2016 Dec; 117(12):2719-2736. PubMed ID: 27064513
[TBL] [Abstract][Full Text] [Related]
3. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
Hara S; Arawaka S; Sato H; Machiya Y; Cui C; Sasaki A; Koyama S; Kato T
Mol Biol Cell; 2013 Jun; 24(11):1649-60, S1-3. PubMed ID: 23576548
[TBL] [Abstract][Full Text] [Related]
4. The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.
Butler EK; Voigt A; Lutz AK; Toegel JP; Gerhardt E; Karsten P; Falkenburger B; Reinartz A; Winklhofer KF; Schulz JB
PLoS Genet; 2012 Feb; 8(2):e1002488. PubMed ID: 22319455
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic Neurons Differentiated from LRRK2 I1371V-Induced Pluripotent Stem Cells Display a Lower Yield, α-Synuclein Pathology, and Functional Impairment.
Jagtap S; Potdar C; Yadav R; Pal PK; Datta I
ACS Chem Neurosci; 2022 Sep; 13(17):2632-2645. PubMed ID: 36006382
[TBL] [Abstract][Full Text] [Related]
6. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
8. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
9. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
Wu W; Sung CC; Yu P; Li J; Chung KKK
PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.
Guo JT; Chen AQ; Kong Q; Zhu H; Ma CM; Qin C
Cell Mol Neurobiol; 2008 Jan; 28(1):35-47. PubMed ID: 17985233
[TBL] [Abstract][Full Text] [Related]
11. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine.
Jain MK; Bhat R
Neurobiol Dis; 2014 Mar; 63():115-28. PubMed ID: 24269918
[TBL] [Abstract][Full Text] [Related]
12. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
[TBL] [Abstract][Full Text] [Related]
13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
[TBL] [Abstract][Full Text] [Related]
15. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
[TBL] [Abstract][Full Text] [Related]
16. Lipid metabolism alterations in the neuronal response to A53T α-synuclein and Fe-induced injury.
Sánchez Campos S; Alza NP; Salvador GA
Arch Biochem Biophys; 2018 Oct; 655():43-54. PubMed ID: 30098984
[TBL] [Abstract][Full Text] [Related]
17. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
18. Rotenone down-regulates HSPA8/hsc70 chaperone protein in vitro: A new possible toxic mechanism contributing to Parkinson's disease.
Sala G; Marinig D; Riva C; Arosio A; Stefanoni G; Brighina L; Formenti M; Alberghina L; Colangelo AM; Ferrarese C
Neurotoxicology; 2016 May; 54():161-169. PubMed ID: 27133439
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells.
Sung JY; Lee HJ; Jeong EI; Oh Y; Park J; Kang KS; Chung KC
Neurosci Lett; 2007 Apr; 416(3):289-93. PubMed ID: 17337120
[TBL] [Abstract][Full Text] [Related]
20. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
